

Swiss Biotech Success Stories award winner 2020

Helsinn



Helsinn is a fully integrated Swiss pharmaceutical group with a strong R&D pipeline and in-licensing targets ready for the next growth phase, thanks to a strong track record, a solid revenue stream in B2B and strong cash flow and cash position.

Helsinn is investing and building market differentiation in B2C in US and China and is owned by a third-generation healthcare entrepreneurial family.

Founded by Dr Gabriele Braglia in 1976 in Ticino, the Helsinn Group has grown globally with over 650 employees, creating jobs in Switzerland, USA, Ireland, Monaco, and in China, including last year's opening of the Chinese commercial division in Shanghai.

Led by Riccardo Braglia and Giorgio Calderari, Helsinn develops innovative solutions to improve the lives of cancer patients. At present, the R&D pipeline is made up of six product candidates in cancer care and rare diseases, including two in Phase III and a total of 26 clinical trials undertaken between 2015-2019 alone. Each year, the Group invests approximately 25% of its profits in R&D.

All of the Group's output is guided and underpinned by core values of quality, integrity, and respect. This belief system, along with strong alliances with service providers and over 80 commercial

partnerships across 190 countries, has helped the Group to develop new treatments to fulfil more medical needs around the world.

Helsinn Group wants to play an active and central role in promoting a social transformation in favor of people and the environment. Corporate social responsibility is at the heart of our daily activities and this confirms our goal of including sustainable growth in the company's strategic plan.

Further demonstrating its commitment to biotech innovation, the Helsinn leadership team established an investment fund to support the future of healthcare and advance early-stage opportunities: providing funding and strategic support to innovative companies.

This outward look at innovation and unwavering determination to push boundaries in healthcare truly makes Helsinn a Swiss Biotech Success Story.